Search Results

Your search for Kathy Holliman, MEd,Kathy Holliman, MEd matches 2 pages

Showing 1 - 2

By Kathy Holliman, MEd / May 25, 2019

ASCO Clinical Opinion Recommends Germline Testing for All Patients With Pancreatic Cancer

The recently released ASCO Clinical Practice Provisional Clinical Opinion on Evaluating Susceptibility to Pancreatic Cancer highlights the importance of emerging data indicating a relatively high rate of germline mutations in pancreatic cancer.1 Recent studies have demonstrated that up to 1 in 10...

prostate cancer

By Kathy Holliman, MEd / March 25, 2019

ASCO Endorses Active Surveillance Guideline for Low-Risk Prostate Cancer

ASCO ENDORSES and reinforces the evidence-based American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) Guideline published in 2018 in the Journal of Urology. ASCO’s endorsement of a guideline on clinically localized...

Dec

Today In Oncology

Search Results

Your search for Kathy Holliman, MEd,Kathy Holliman, MEd matches 2 pages

ASCO Clinical Opinion Recommends Germline Testing for All Patients With Pancreatic Cancer

ASCO Endorses Active Surveillance Guideline for Low-Risk Prostate Cancer

Combination of Two Oral Agents May Improve Progression Free Survival in Patients With Previously Untreated CLL

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive Relapsed Refractory Mantle Cell Lymphoma

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer

SEQUOIA 5-Year Follow-up Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL